These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 26887552

  • 21. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
    Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, Rönnelid J.
    Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
    [Abstract] [Full Text] [Related]

  • 22. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L, Szekanecz Z, Szabó Z, Fekete A, Zeher M, Horváth IF, Dankó K, Kapitány A, Végvári A, Sipka S, Szegedi G, Lakos G.
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [Abstract] [Full Text] [Related]

  • 23. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
    Derganova O, Martinez-Gamboa L, Egerer K, Bang H, Fredenhagen G, Roggenbuck D, Esaulenko I, Burmester GR, Chernykh T, Feist E.
    Clin Exp Rheumatol; 2014 Aug; 32(5):622-9. PubMed ID: 25189876
    [Abstract] [Full Text] [Related]

  • 24. [Comparison and relevance of rheumatoid factors, antikeratin antibodies and anti-cyclic citrullinated peptides antibodies in rheumatoid arthritis].
    Galati S, Beauvillain C, Renier G, Jeannin P, Masson C, Chevailler A.
    Ann Biol Clin (Paris); 2008 Aug; 66(2):157-64. PubMed ID: 18390426
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR.
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Predictive values of anti-cyclic citrullinated peptide antibody, antikeratin antibody and rheumatoid factor in diagnosing articular erosions in patients with rheumatoid arthritis].
    Xie QB, Yin G.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):508-12. PubMed ID: 19627016
    [Abstract] [Full Text] [Related]

  • 31. The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis.
    Shovman O, Gilburd B, Zandman-Goddard G, Sherer Y, Orbach H, Gerli R, Shoenfeld Y.
    Clin Dev Immunol; 2005 Sep; 12(3):197-202. PubMed ID: 16295525
    [Abstract] [Full Text] [Related]

  • 32. [Comparative characteristics of specific autoantibodies in rheumatoid arthritis].
    Lapin SV, Maslianskiĭ AL, Mazurov VI, Totolian AA.
    Ter Arkh; 2005 Sep; 77(12):53-9. PubMed ID: 16514821
    [Abstract] [Full Text] [Related]

  • 33. Clinical diagnostic significance of 14-3-3η protein, high-mobility group box-1, anti-cyclic citrullinated peptide antibodies, anti-mutated citrullinated vimentin antibodies and rheumatoid factor in rheumatoid arthritis.
    Huang J, Zeng T, Zhang X, Tian Y, Wu Y, Yu J, Pei Z, Liu Y, Hu T, Tan L.
    Br J Biomed Sci; 2020 Jan; 77(1):19-23. PubMed ID: 31433746
    [Abstract] [Full Text] [Related]

  • 34. [Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
    Us D, Gülmez D, Hasçelik G.
    Mikrobiyol Bul; 2003 Jan; 37(2-3):163-70. PubMed ID: 14593899
    [Abstract] [Full Text] [Related]

  • 35. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis.
    van Rossum M, van Soesbergen R, de Kort S, ten Cate R, Zwinderman AH, de Jong B, Dijkmans B, van Venrooij WJ.
    J Rheumatol; 2003 Apr; 30(4):825-8. PubMed ID: 12672206
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.